Open label, controlled, randomized, 2-arm Phase II clinical trial to assess the safety and efficacy of BNT113 in combination with pembrolizumab in patients with unresectable, recurrent, or metastatic HPV16+ Head and Neck Squamous Cell Carcinoma (HNSCC) expressing PD- L1 with a combined positive score (CPS) ≥ 1.